Icon of the Instituts for Quality and Efficiency in Health Care

[A25-98] Durvalumab (NSCLC, neoadjuvant + adjuvant) – Benefit assessment according to §35a Social Code Book V

Last updated 03.11.2025

Project no.:
A25-98

Commission:
Commission awarded on 30.07.2025 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Topic:
Cancer

Indication:

Adults with resectable non-small cell lung cancer at high risk of recurrence and without epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements; neoadjuvant and adjuvant therapy

Result of dossier assessment:

Added benefit not proven

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

DOI:

https://doi.org/10.60584/A25-98

Project no. Title Status
A24-87 Durvalumab (endometrial cancer) – Benefit assessment according to §35a Social Code Book V Commission completed
A24-86 Durvalumab (first-line in combination with carboplatin and paclitaxel, maintenance in combination with olaparib; endometrial cancer) – Benefit assessment according to §35a Social Code Book V Commission completed
A23-138 Durvalumab (HCC) – Benefit assessment according to §35a Social Code Book V Commission completed
A23-27 Durvalumab (hepatocellular carcinoma [HCC]) – Benefit assessment according to §35a Social Code Book V Commission completed
A23-30 Tremelimumab (hepatocellular carcinoma [HCC]) – Benefit assessment according to §35a Social Code Book V Commission completed
A23-29 Tremelimumab (NSCLC) – Benefit assessment according to §35a Social Code Book V Commission completed
A23-31 Durvalumab (NSCLC) – Benefit assessment according to §35a Social Code Book V Commission completed
A23-26 Durvalumab (malignant biliary cystic tumour [BCT]) – Benefit assessment according to §35a Social Code Book V Commission completed
A20-87 Durvalumab (small cell lung cancer) - Benefit assessment according to §35a Social Code Book V Commission completed
A18-69 Durvalumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V Commission completed
A25-96 Durvalumab (small cell lung cancer, non-advanced) – Benefit assessment according to § 35a SGB V Commission completed
A25-97 Durvalumab (urothelial carcinoma) – Benefit assessment according to § 35a SGB V Commission completed

Contact

Press contact

+49 221 356850

presse@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page